Effective today, October 17, 2017, PathGroup offers a new test for Cystic Fibrosis (CF) Carrier Screening. In our effort to provide the most innovative and clinically applicable tests available, this new test includes 175 clinically relevant CFTR mutations, which improves the CFTR mutation detection rate across all ethnicities, particularly African Americans and Hispanic Americans. Professional medical organizations, including ACOG, recommend CF carrier screening be offered to all patients.1
For More Information, CLICK HERE